查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1344312

視網膜生物製劑市場：依藥物類別、適應症、通路分類：2023-2032 年全球機會分析與產業預測

Retinal Biologics Market By Drug Class, By Indication, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 243 Pages | 商品交期: 2-3個工作天內

價格

2022年，視網膜生物製劑市場估值為149億美元，預計2023年至2032年複合年增長率為5.1%，到2032年將達到247億美元。

視網膜生物製劑市場-IMG1

用於治療視網膜疾病的最著名的生物製劑之一是雷珠單抗（商品名 Lucentis），用於治療老年性黃斑部病變和黃斑部水腫。 阿柏西普（商品名 Eylea）是另一種常用的生物藥物，針對老年黃斑部病變、糖尿病視網膜病變和視網膜靜脈阻塞。 貝伐珠單抗（商品名阿瓦斯汀）主要被批准用於癌症治療，但它也被用於眼科適應症外的類似適應症。

由於視網膜疾病盛行率不斷上升、患有視網膜疾病的老年人口不斷增加以及生物技術和眼科研究的進步，視網膜生物製品市場正在經歷顯著增長。 例如，根據NCBI統計，2020年全球約有1.96億人受到AMD影響，全球盛行率為8.69%。 患者和醫療保健專業人員對生物製劑的有效性和益處的認識不斷提高也推動了市場的成長。

此外，視網膜生物製劑領域正在進行的研究和開發也有助於市場成長。 製藥公司、學術機構和研究組織正在投資發現和開發創新療法、提高治療效果並擴大可用的視網膜生物製劑的範圍。 例如，Atsena Therapeutics Inc. 正在進行一項臨床試驗，以評估 ATSN-201 在患有 RS1 相關 X 連鎖視網膜病變 (XLRS) 的 6 至 64 歲男性中的安全性和耐受性。

此外，基因工程、重組 DNA 技術和標靶藥物傳輸系統等生物技術的進步正在徹底改變視網膜生物製劑領域並支持市場成長。 這些進步使得開發出高度針對性和有效的治療方法，專門解決視網膜疾病的根本機制，改善治療結果並推動市場成長。 然而，視網膜治療的高成本可能會限制視網膜生物製劑的採用並抑制市場成長。

目錄

第一章簡介

第 2 章執行摘要

第三章市場概述

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 多個組織增加策略性舉措
      • 視網膜疾病的盛行率不斷上升
      • 老年人口增加
    • 抑制因素
      • 生物製品價格高企
    • 機會
      • 新興市場的成長機會
      • 增加研發活動
  • 新冠肺炎 (COVID-19) 市場影響分析

第 4 章視網膜生物製品市場：依藥物類別

  • 摘要
  • VEGF-A拮抗劑
  • 其他

第五章視網膜生物製劑市場：按適應症

  • 摘要
  • 黃斑部病變
  • 糖尿病視網膜病變
  • 其他

第 6 章視網膜生物製劑市場：依通路劃分

  • 摘要
  • 醫院藥房
  • 藥局和零售藥局
  • 線上提供者

第 7 章視網膜生物製品市場：依地區

  • 摘要
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 韓國
    • 其他亞太地區
  • 拉丁美洲
    • 拉丁美洲
    • 中東/非洲

第八章競爭態勢

  • 簡介
  • 關鍵成功策略
  • 10家主要公司的產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022 年主要公司的定位

第九章公司簡介

  • F. Hoffmann-La Roche Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Biogen
  • Novartis AG
  • Coherus BioSciences, Inc.
  • Bayer AG
  • AbbVie Inc.
  • Biocon
  • Outlook Therapeutics, Inc.
  • Amgen Inc.
Product Code: A10946

According to a new report published by Allied Market Research, titled, "Retinal Biologics Market," The retinal biologics market was valued at $14.9 billion in 2022, and is estimated to reach $24.7 billion by 2032, growing at a CAGR of 5.1% from 2023 to 2032.

Retinal Biologics Market - IMG1

One of the most well-known biologics used in the treatment of retinal conditions is Ranibizumab (brand name Lucentis), which is used for age-related macular degeneration and macular edema. Another commonly used biologic is aflibercept (brand name Eylea), which targets AMD age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Bevacizumab (brand name Avastin), although primarily approved for cancer treatment, is sometimes used off-label in ophthalmology for similar indications.

The retina biologics market has experienced significant growth owing to rise in prevalence of retinal diseases, rise in geriatric population suffering from retinal disorders diseases, and advancements in biotechnology and ophthalmic research. For instance, according to the (NCBI) in 2020, approximately 196 million people worldwide to affected by AMD, with a global prevalence of 8.69%. In addition, increase in awareness among patients and healthcare professionals about the efficacy and benefits of biologic therapies drive the market growth.

Furthermore, ongoing research and development activities in the field of retinal biologics contribute to market growth. Pharmaceutical companies, academic institutions, and research organizations invest in discovering and developing innovative therapies, improving treatment efficacy, and expanding the range of available retinal biologics. For instance, Atsena Therapeutics Inc. conducting a clinical trial to evaluate the safety and tolerability of ATSN-201 in male subjects 6 to 64 years old with RS1-associated X-linked retinoschisis (XLRS).

Moreover, advances in biotechnology, such as genetic engineering, recombinant DNA technology, and targeted drug delivery systems, have revolutionized the field of retinal biologics that support the market growth. These advancements have enabled the development of highly targeted and efficacious therapies that specifically address the underlying mechanisms of retinal diseases, improving treatment outcomes and driving the market growth. However, high cost of retinal drugs may limit the adoption of retinal biologic drugs and restrain the market growth.

The retinal biologics market is segmented into drug class, indication, distribution channel, and region. On the basis of drug class, the market is bifurcated into VEGF-A antagonist and others. The VEGF-A antagonist segment is further categorized into Aflibercept, Ranibizumab, and others. On the basis of indication, the market is categorized into macular degeneration, diabetic retinopathy, and others. On the basis of distribution channel, the market is categorized into hospital pharmacies, drug stores and retail pharmacies, and online providers. On the basis of, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).

Major key players that operate in the retinal biologics market are AbbVie Inc., Amgen Inc., Bayer AG, Biocon, Biogen, Coherus BioSciences, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Outlook Therapeutics, Inc., and Regeneron Pharmaceuticals, Inc. Key players have adopted product launch, product approval, and collaboration as key developmental strategies to improve the product portfolio of the retinal biologics market.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the retinal biologics market analysis from 2022 to 2032 to identify the prevailing retinal biologics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the retinal biologics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global retinal biologics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Distribution Channel

  • Hospital Pharmacies
  • Online Providers
  • Drug Stores and Retail Pharmacies

By Drug Class

  • VEGF-A Antagonist
    • Type
    • Aflibercept
    • Ranibizumab
    • Others
  • Others

By Indication

  • Macular Degeneration
  • Diabetic Retinopathy
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East And Africa

Key Market Players:

    • AbbVie Inc.
    • Amgen Inc.
    • Bayer AG
    • Biocon
    • Biogen
    • Coherus BioSciences, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Outlook Therapeutics, Inc.
    • Regeneron Pharmaceuticals, Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in strategic Initiatives by several organizations
      • 3.4.1.2. Increase in prevalence of retinal diseases
      • 3.4.1.3. Increase in geriatric population
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of biologic drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in emerging markets
      • 3.4.3.2. Rise in R&D activities
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: RETINAL BIOLOGICS MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. VEGF-A Antagonist
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. VEGF-A Antagonist Retinal Biologics Market by Type
  • 4.3. Others
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: RETINAL BIOLOGICS MARKET, BY INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Macular Degeneration
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Diabetic Retinopathy
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug Stores and Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: RETINAL BIOLOGICS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drug Class
    • 7.2.3. Market size and forecast, by Indication
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drug Class
      • 7.2.5.1.3. Market size and forecast, by Indication
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drug Class
      • 7.2.5.2.3. Market size and forecast, by Indication
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drug Class
      • 7.2.5.3.3. Market size and forecast, by Indication
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drug Class
    • 7.3.3. Market size and forecast, by Indication
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drug Class
      • 7.3.5.1.3. Market size and forecast, by Indication
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drug Class
      • 7.3.5.2.3. Market size and forecast, by Indication
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drug Class
      • 7.3.5.3.3. Market size and forecast, by Indication
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drug Class
      • 7.3.5.4.3. Market size and forecast, by Indication
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drug Class
      • 7.3.5.5.3. Market size and forecast, by Indication
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drug Class
      • 7.3.5.6.3. Market size and forecast, by Indication
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drug Class
    • 7.4.3. Market size and forecast, by Indication
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drug Class
      • 7.4.5.1.3. Market size and forecast, by Indication
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drug Class
      • 7.4.5.2.3. Market size and forecast, by Indication
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drug Class
      • 7.4.5.3.3. Market size and forecast, by Indication
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drug Class
      • 7.4.5.4.3. Market size and forecast, by Indication
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Drug Class
      • 7.4.5.5.3. Market size and forecast, by Indication
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Drug Class
      • 7.4.5.6.3. Market size and forecast, by Indication
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drug Class
    • 7.5.3. Market size and forecast, by Indication
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Latin America
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drug Class
      • 7.5.5.1.3. Market size and forecast, by Indication
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Middle East And Africa
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drug Class
      • 7.5.5.2.3. Market size and forecast, by Indication
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. F. Hoffmann-La Roche Ltd.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Regeneron Pharmaceuticals, Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Biogen
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Novartis AG
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Coherus BioSciences, Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Bayer AG
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. AbbVie Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Biocon
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Outlook Therapeutics, Inc.
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
  • 9.10. Amgen Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 02. RETINAL BIOLOGICS MARKET FOR VEGF-A ANTAGONIST, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GLOBAL VEGF-A ANTAGONIST RETINAL BIOLOGICS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 04. RETINAL BIOLOGICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 06. RETINAL BIOLOGICS MARKET FOR MACULAR DEGENERATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. RETINAL BIOLOGICS MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. RETINAL BIOLOGICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 10. RETINAL BIOLOGICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. RETINAL BIOLOGICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. RETINAL BIOLOGICS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. RETINAL BIOLOGICS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA RETINAL BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 18. U.S. RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 19. U.S. RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 20. U.S. RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. CANADA RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 22. CANADA RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 23. CANADA RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE RETINAL BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. UK RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 38. UK RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 39. UK RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. ITALY RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 41. ITALY RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 42. ITALY RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC RETINAL BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. CHINA RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 57. CHINA RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 58. CHINA RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. INDIA RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 60. INDIA RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 61. INDIA RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. LAMEA RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA RETINAL BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 75. LATIN AMERICA RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 76. LATIN AMERICA RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 77. LATIN AMERICA RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. MIDDLE EAST AND AFRICA RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 79. MIDDLE EAST AND AFRICA RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 80. MIDDLE EAST AND AFRICA RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 81. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 82. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 83. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 84. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 85. REGENERON PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 86. REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 87. REGENERON PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
  • TABLE 88. REGENERON PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 89. BIOGEN: KEY EXECUTIVES
  • TABLE 90. BIOGEN: COMPANY SNAPSHOT
  • TABLE 91. BIOGEN: PRODUCT SEGMENTS
  • TABLE 92. BIOGEN: PRODUCT PORTFOLIO
  • TABLE 93. BIOGEN: KEY STRATERGIES
  • TABLE 94. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 95. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 96. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 97. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 98. NOVARTIS AG: KEY STRATERGIES
  • TABLE 99. COHERUS BIOSCIENCES, INC.: KEY EXECUTIVES
  • TABLE 100. COHERUS BIOSCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 101. COHERUS BIOSCIENCES, INC.: PRODUCT SEGMENTS
  • TABLE 102. COHERUS BIOSCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 103. COHERUS BIOSCIENCES, INC.: KEY STRATERGIES
  • TABLE 104. BAYER AG: KEY EXECUTIVES
  • TABLE 105. BAYER AG: COMPANY SNAPSHOT
  • TABLE 106. BAYER AG: PRODUCT SEGMENTS
  • TABLE 107. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 108. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 109. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 110. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 111. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 112. ABBVIE INC.: KEY STRATERGIES
  • TABLE 113. BIOCON: KEY EXECUTIVES
  • TABLE 114. BIOCON: COMPANY SNAPSHOT
  • TABLE 115. BIOCON: PRODUCT SEGMENTS
  • TABLE 116. BIOCON: PRODUCT PORTFOLIO
  • TABLE 117. OUTLOOK THERAPEUTICS, INC.: KEY EXECUTIVES
  • TABLE 118. OUTLOOK THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 119. OUTLOOK THERAPEUTICS, INC.: PRODUCT SEGMENTS
  • TABLE 120. OUTLOOK THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 121. AMGEN INC.: KEY EXECUTIVES
  • TABLE 122. AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 123. AMGEN INC.: PRODUCT SEGMENTS
  • TABLE 124. AMGEN INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. RETINAL BIOLOGICS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF RETINAL BIOLOGICS MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN RETINAL BIOLOGICS MARKET (2023-2032)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE INTENSITY OF RIVALRY
  • FIGURE 08. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALRETINAL BIOLOGICS MARKET
  • FIGURE 09. RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022(%)
  • FIGURE 10. COMPARATIVE SHARE ANALYSIS OF RETINAL BIOLOGICS MARKET FOR VEGF-A ANTAGONIST, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF RETINAL BIOLOGICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. RETINAL BIOLOGICS MARKET, BY INDICATION, 2022(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF RETINAL BIOLOGICS MARKET FOR MACULAR DEGENERATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF RETINAL BIOLOGICS MARKET FOR DIABETIC RETINOPATHY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF RETINAL BIOLOGICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF RETINAL BIOLOGICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF RETINAL BIOLOGICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF RETINAL BIOLOGICS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. RETINAL BIOLOGICS MARKET BY REGION, 2022
  • FIGURE 21. U.S. RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 22. CANADA RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. MEXICO RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. GERMANY RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. FRANCE RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. UK RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. ITALY RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. SPAIN RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. REST OF EUROPE RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. JAPAN RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. CHINA RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. INDIA RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. AUSTRALIA RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. SOUTH KOREA RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. REST OF ASIA-PACIFIC RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. LATIN AMERICA RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. MIDDLE EAST AND AFRICA RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 39. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 40. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 41. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 42. COMPETITIVE DASHBOARD
  • FIGURE 43. COMPETITIVE HEATMAP: RETINAL BIOLOGICS MARKET
  • FIGURE 44. TOP PLAYER POSITIONING, 2022
  • FIGURE 45. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 46. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 47. REGENERON PHARMACEUTICALS, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 48. BIOGEN: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 49. BIOGEN: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 50. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 52. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. COHERUS BIOSCIENCES, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 56. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 57. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 58. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 59. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 60. BIOCON: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 61. BIOCON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)